Validation of a Dynamic Risk Prediction Model Incorporating Prior Mammograms in a Diverse Population
- PMID: 40478575
- PMCID: PMC12144620
- DOI: 10.1001/jamanetworkopen.2025.12681
Validation of a Dynamic Risk Prediction Model Incorporating Prior Mammograms in a Diverse Population
Abstract
Importance: For breast cancer risk prediction to be clinically useful, it must be accurate and applicable to diverse groups of women across multiple settings.
Objective: To examine whether a dynamic risk prediction model incorporating prior mammograms, previously validated in Black and White women, could predict future risk of breast cancer across a racially and ethnically diverse population in a population-based screening program.
Design, setting, and participants: This prognostic study included women aged 40 to 74 years with 1 or more screening mammograms drawn from the British Columbia Breast Screening Program from January 1, 2013, to December 31, 2019, with follow-up via linkage to the British Columbia Cancer Registry through June 2023. This provincial, organized screening program offers screening mammography with full field digital mammography (FFDM) every 2 years. Data were analyzed from May to August 2024.
Exposure: FFDM-based, artificial intelligence-generated mammogram risk score (MRS), including up to 4 years of prior mammograms.
Main outcomes and measures: The primary outcomes were 5-year risk of breast cancer (measured with the area under the receiver operating characteristic curve [AUROC]) and absolute risk of breast cancer calibrated to the US Surveillance, Epidemiology, and End Results incidence rates.
Results: Among 206 929 women (mean [SD] age, 56.1 [9.7] years; of 118 093 with data on race, there were 34 266 East Asian; 1946 Indigenous; 6116 South Asian; and 66 742 White women), there were 4168 pathology-confirmed incident breast cancers diagnosed through June 2023. Mean (SD) follow-up time was 5.3 (3.0) years. Using up to 4 years of prior mammogram images in addition to the most current mammogram, a 5-year AUROC of 0.78 (95% CI, 0.77-0.80) was obtained based on analysis of images alone. Performance was consistent across subgroups defined by race and ethnicity in East Asian (AUROC, 0.77; 95% CI, 0.75-0.79), Indigenous (AUROC, 0.77; 95% CI 0.71-0.83), and South Asian (AUROC, 0.75; 95% CI 0.71-0.79) women. Stratification by age gave a 5-year AUROC of 0.76 (95% CI, 0.74-0.78) for women aged 50 years or younger and 0.80 (95% CI, 0.78-0.82) for women older than 50 years. There were 18 839 participants (9.0%) with a 5-year risk greater than 3%, and the positive predictive value was 4.9% with an incidence of 11.8 per 1000 person-years.
Conclusions and relevance: A dynamic MRS generated from both current and prior mammograms showed robust performance across diverse racial and ethnic populations in a province-wide screening program starting from age 40 years, reflecting improved accuracy for racially and ethnically diverse populations.
Conflict of interest statement
Figures



Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance Expansion.JAMA Netw Open. 2025 Aug 1;8(8):e2525216. doi: 10.1001/jamanetworkopen.2025.25216. JAMA Netw Open. 2025. PMID: 40762915 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.Health Technol Assess. 2011 Sep;15(34):v-vi, 1-322. doi: 10.3310/hta15340. Health Technol Assess. 2011. PMID: 21951942 Free PMC article.
-
Artificial Intelligence Algorithm for Subclinical Breast Cancer Detection.JAMA Netw Open. 2024 Oct 1;7(10):e2437402. doi: 10.1001/jamanetworkopen.2024.37402. JAMA Netw Open. 2024. PMID: 39361281 Free PMC article.
References
-
- US Food and Drug Administration. Important information: final rule to amend the mammography quality standards act (MQSA). Updated September 10, 2024. Accessed May 1, 2025. https://www.fda.gov/radiation-emitting-products/mammography-quality-stan...
-
- Collister JA, Liu X, Littlejohns TJ, Cuzick J, Clifton L, Hunter DJ. Assessing the value of incorporating a polygenic risk score with nongenetic factors for predicting breast cancer diagnosis in the UK Biobank. Cancer Epidemiol Biomarkers Prev. 2024;33(6):812-820. doi:10.1158/1055-9965.EPI-23-1432 - DOI - PMC - PubMed
-
- Anandarajah A, Chen Y, Colditz GA, Hardi A, Stoll C, Jiang S. Studies of parenchymal texture added to mammographic breast density and risk of breast cancer: a systematic review of the methods used in the literature. Breast Cancer Res. 2022;24(1):101. doi:10.1186/s13058-022-01600-5 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical